Foster City, CA, United States of America

Chen Mao

USPTO Granted Patents = 13 (Patent Applications = 13)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Redwood City, CA (US) (2013 - 2014)
Mountain View, CA (US) (2016 - 2017)
Foster City, CA (US) (2017 - 2022)

Company Filing History:

Arbor Pharmaceuticals, LLC

patents

Years Active: 2013-2022

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11365197 - Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase (2022-06-21),

2. 10940117 - Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof (2021-03-09),

3. 10716760 - Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof (2020-07-21),

4. 10246461 - Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase (2019-04-02),

5. 9895336 - Crystalline forms of (N, N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2018-02-20),

6. 9795581 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2017-10-24),

7. 9682057 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2017-06-20),

8. 9597292 - Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof (2017-03-21),

9. 9421182 - Cocrystals of dimethyl fumarate (2016-08-23),

10. 9416096 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2016-08-16),

11. 8722733 - Levodopa prodrug mesylate hydrate (2014-05-13),

12. 8435562 - Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use (2013-05-07),

13. 8399513 - Levodopa prodrug mesylate hydrate (2013-03-19),

Title: Inventor Profile: Chen Mao

Introduction

Chen Mao, based in Foster City, California, is an accomplished inventor with a notable portfolio of 13 patents. His contributions primarily focus on innovative formulations and dosage forms that have the potential to improve treatment methods for various diseases.

Latest Patents

Among his latest inventions, Chen Mao has developed dosage form compositions that comprise an inhibitor of Bruton's tyrosine kinase. This invention relates to crystalline mesylate salts, crystalline chloride salts, and crystalline sulfate salts of a specific compound that serves as an inhibitor of Bruton's tyrosine kinase. In some instances, these crystalline salts are single polymorphs. Additionally, he has created improved oral dosage forms of methyl hydrogen fumarate and its prodrugs. These advancements offer new methods for treating diseases such as multiple sclerosis and psoriasis using these optimized dosage forms.

Career Highlights

Throughout his career, Chen Mao has made significant strides in the pharmaceutical industry. He has been associated with reputable companies such as Xenoport, Inc. and Genentech, Inc. His work has focused on the development of cutting-edge solutions that address complex health issues.

Collaborations

Chen has worked alongside a talented team of professionals, including Sami Karaborni and Randall A Scheuerman. These collaborations have enhanced his research capabilities and contributed to the success of his innovative projects.

Conclusion

Chen Mao continues to be a distinguished figure in the field of pharmaceutical inventions. His 13 patents reflect his commitment to advancing medical science and improving patient care through innovative solutions. As the industry evolves, inventors like him play a crucial role in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.